xMedulloblastoma is one of the most common malignant childhood brain tumors. Although advances in multimodal treatment have significantly improved the survival rate, the outcome of children is still very poor. Therefore, there is an urgent need to develop novel approaches that can increase survival and reduce long term side effects of patients. Histone deacetylase inhibitors (HDIs) have emerged as a promising new class of antineoplastic agents in cancer therapy. Among them, suberoylanilide hydroxamic acid (SAHA, vorinostat, Zolinza®) is a highly potential HDI which has been approved for treatment of cutaneous T-cell lymphoma and is currently used for treatment of various tumor cell types both in vivo and in vitro. However, only little infor...
HDAC inhibitors (HDACI), a new class of anticancer agents, induce apoptosis in many cancer entities....
Histone deacetylase inhibitors (HDACi), such as suberoylanilide hydroxamic acid (SAHA), have been sh...
Suberoylanilide hydroxamic acid (SAHA) is a well-known pan HDAC inhibitor, and its clinical applicat...
Emerging evidence suggests that suberoylanilide hydroxamic acid (SAHA), a clinically approved HDAC i...
Introduction: Medulloblastoma (MB) is the most frequent malignant brain tumor in children. Four subg...
Purpose: The present in vitro study was conducted to evaluate the effects of the histone deacetylase...
Suberoylanilide hydroxamic acid (SAHA), an orally administered inhibitor of histone deacetylases, is...
Epigenetic dysregulations are linked to many human diseases including neurodegenerative disorders, i...
Objective. Our study analyzed the effects of HDAC inhibitor SAHA treatment on gene expressions of Ch...
© 2003 American Association for Cancer ResearchPurpose: A group of histone deacetylase inhibitors ha...
SAHA (suberoylanilide hydroxamic acid or vorinostat) is the first nonselective histone deacetylase (...
Gene expression is often altered by epigenetic modifications that can significantly influence the gr...
Glioblastoma is the most malignant and prevalent brain tumor in adults. It can grow and spread quick...
Histone deacetylase (HDAC) inhibitors represent a promising group of anticancer agents. This paper s...
Histone deacetylase inhibitors (HDACi), such as suberoylanilide hydroxamic acid (SAHA), have been sh...
HDAC inhibitors (HDACI), a new class of anticancer agents, induce apoptosis in many cancer entities....
Histone deacetylase inhibitors (HDACi), such as suberoylanilide hydroxamic acid (SAHA), have been sh...
Suberoylanilide hydroxamic acid (SAHA) is a well-known pan HDAC inhibitor, and its clinical applicat...
Emerging evidence suggests that suberoylanilide hydroxamic acid (SAHA), a clinically approved HDAC i...
Introduction: Medulloblastoma (MB) is the most frequent malignant brain tumor in children. Four subg...
Purpose: The present in vitro study was conducted to evaluate the effects of the histone deacetylase...
Suberoylanilide hydroxamic acid (SAHA), an orally administered inhibitor of histone deacetylases, is...
Epigenetic dysregulations are linked to many human diseases including neurodegenerative disorders, i...
Objective. Our study analyzed the effects of HDAC inhibitor SAHA treatment on gene expressions of Ch...
© 2003 American Association for Cancer ResearchPurpose: A group of histone deacetylase inhibitors ha...
SAHA (suberoylanilide hydroxamic acid or vorinostat) is the first nonselective histone deacetylase (...
Gene expression is often altered by epigenetic modifications that can significantly influence the gr...
Glioblastoma is the most malignant and prevalent brain tumor in adults. It can grow and spread quick...
Histone deacetylase (HDAC) inhibitors represent a promising group of anticancer agents. This paper s...
Histone deacetylase inhibitors (HDACi), such as suberoylanilide hydroxamic acid (SAHA), have been sh...
HDAC inhibitors (HDACI), a new class of anticancer agents, induce apoptosis in many cancer entities....
Histone deacetylase inhibitors (HDACi), such as suberoylanilide hydroxamic acid (SAHA), have been sh...
Suberoylanilide hydroxamic acid (SAHA) is a well-known pan HDAC inhibitor, and its clinical applicat...